ARQ 621
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Solid Tumors, Refractory/Relapsed Hematologic Malignancies
Conditions
Metastatic Solid Tumors, Refractory/Relapsed Hematologic Malignancies
Trial Timeline
Aug 1, 2009 → Sep 1, 2011
NCT ID
NCT00825487About ARQ 621
ARQ 621 is a phase 1 stage product being developed by Merck for Metastatic Solid Tumors, Refractory/Relapsed Hematologic Malignancies. The current trial status is completed. This product is registered under clinical trial identifier NCT00825487. Target conditions include Metastatic Solid Tumors, Refractory/Relapsed Hematologic Malignancies.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00825487 | Phase 1 | Completed |
Competing Products
20 competing products in Metastatic Solid Tumors, Refractory/Relapsed Hematologic Malignancies